Updates are available Correction dated 2022-11-14

Article History

Received: 22 February 2021

Accepted: 17 August 2022

First Online: 7 September 2022

Change Date: 14 November 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41467-022-34580-3

Competing interests

: V.S. received non-commercial research support from Novartis and Genentech. M.B. reported receiving honoraria for speaker activities and advisory role from Pfizer, Novartis and Elli-Lilly and support for travel expenses from Roche and Pfizer. M.O. declares grant/research support (to the Institution) from AstraZeneca, Philips Healthcare, Genentech, Roche, Novartis, Immunomedics, Seattle Genetics, GSK, Boehringer-Ingelheim, PUMA Biotechnology, and Zenith Epigenetics; consultant role for Roche, GSK, PUMA Biotechnology, AstraZeneca, and Seattle Genetics; and has received honoraria from Roche, Seattle Genetics, and Novartis. G.V. reported receiving honoraria for speaker activities from MDS and advisory role from Astrazeneca. F.S. is employee of Novartis. K.L. is employee of Genentech. C.C. is a member of AstraZeneca’s External Science Panel, of Illumina’s Scientific Advisory Board, and is a recipient of research grants (administered by the University of Cambridge) from AstraZeneca, Genentech, Roche and Servier. J.A. has received research funds from Roche, Synthon, Menarini, and Molecular Partners and consultancy honoraria from Menarini. A.P. reports that his institution received research funding from Nanostring Technologies, Roche and Novartis and reports consulting and lecture fees from Nanostring Technologies, Roche, Novartis, Pfizer, Oncolytics Biotech, Amgen, Elli-Lilly, MSD and PUMA. P.N. has consulted for Bayer, Novartis, and MSD and received compensation. R.D. is on advisory role of AstraZeneca, Roche and Boehringer-Ingelheim and has received speaker’s fees from Roche, Symphogen, IPSEN, Amgen, Servier, Sanofi, MSD, and research support from Merck. M.S. is on the scientific advisory board of Menarini Ricerche and the Bioscience Institute, has received research funds from Puma Biotechnology, Daiichi-Sankio, AstraZeneca, Targimmune, Immunomedics and Menarini Ricerche, and is a cofounder of Medendi.org. M.A. received a research grant from Eli-Lilly, honoraria from Novartis, Astrazeneca, Seattle Genetics, Abbvie and Pfizer and travel grants from Novartis, Roche, Pfizer. S.M. has provide punctual statistical advice to IDDI and Janssen Cilag and participated to data and safety monitoring committees of clinical trials (Hexal, Steba, IQVIA, Roche, Sensorion, Biophytis, Servier, Yuhan), outside the submitted work. C.S. has served as consultant, participated in advisory boards or received travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Roche, Genomic Health, Merck, Sharp and Dhome España S.A., Novartis Odonate Therapeutics, Pfizer, Philips He. C.Ve. & S.K. are founders of Sinopsee Therapeutics and Aplomex; neither company has any conflict with the current work. VHIO has had funding (paid directly to the Institution) from AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Genentech, Immunomedics, Macrogenics, Merck, Sharp and Dhome España S.A., Novartis, Pfizer, Piqur Therapeutics, Puma, Roche, Synthon and Zenith Pharma. The remaining authors declare no competing interests.